EUVIMEDEUVIMED entdecken
Crossref

LC‐ESI‐MS/MS method validation for simultaneous quantification of FDA‐approved anticancer agents futibatinib and binimetinib in rat plasma: Insights from preclinical pharmacokinetics

Shailesh D Dadge iD, Shubhi Yadav, Shivam Rathaur, Jiaur R Gayen iD

Biomedical Chromatography · 2024-11 · 38 (11)

DOI: 10.1002/bmc.6005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 05.09.2024. Verfasst von Shailesh D Dadge und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutics & Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, 226031, India. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Antineoplastic Agents, Benzimidazoles, Rats, Sprague-Dawley. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study investigates the combination of FGFR inhibitor futibatinib (FTB) and MEK inhibitor binimetinib (BTB) for KRASmt NSCLC therapy. An analytical method was developed and validated for measuring FTB and BTB concentrations in rat plasma, adhering to USFDA guidelines. Using liquid–liquid extraction on 45‐μL plasma samples, a 6.5‐min run time was achieved. The linear calibration curve ranged from 2 to 100 ng/mL. Intra‐day and inter‐day accuracy ranged between 92.06% and 100.08%. Four blank injections post high‐concentration samples resolved significant carryover. Extraction recoveries averaged 92.06% to 102.37% across concentrations. No significant endogenous interference was detected in blank plasma. The LLOQ for both drugs was 2.0 ng/mL. Selectivity, matrix effects, stability, and dilution integrity met the acceptance criteria. The method assessed FTB and BTB interaction potential in combination therapy at 5 mg/kg. The findings provide essential pharmacokinetics insights for future clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tandem Mass SpectrometryAntineoplastic AgentsBenzimidazolesRats, Sprague-DawleyAnimalsRatsReproducibility of ResultsLinear ModelsMaleChromatography, LiquidSpectrometry, Mass, Electrospray IonizationLimit of Detection

Stichwörter der Autor:innen

FGFRKRASmtLC–MS/MSMEKbinimetinibfutibatinib

Substanzen

binimetinibAntineoplastic AgentsBenzimidazoles

Autor:innen und Institutionen

  • Pharmaceutics & Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, 226031, India.
  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India.
  • Pharmacology Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India.

ORCID-Profile: Shailesh D Dadge, Jiaur R Gayen

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Dadge, S. D., Yadav, S., Rathaur, S., & Gayen, J. R. (2024). LC‐ESI‐MS/MS method validation for simultaneous quantification of FDA‐approved anticancer agents futibatinib and binimetinib in rat plasma: Insights from preclinical pharmacokinetics. Biomedical Chromatography, 38(11). https://doi.org/10.1002/bmc.6005

Vancouver

Dadge SD, Yadav S, Rathaur S, Gayen JR. LC‐ESI‐MS/MS method validation for simultaneous quantification of FDA‐approved anticancer agents futibatinib and binimetinib in rat plasma: Insights from preclinical pharmacokinetics. Biomedical Chromatography. 2024;38(11). doi:10.1002/bmc.6005

BibTeX
@article{Dadge2024,
  author = {Dadge, Shailesh D and Yadav, Shubhi and Rathaur, Shivam and Gayen, Jiaur R},
  title = {LC‐ESI‐MS/MS method validation for simultaneous quantification of FDA‐approved anticancer agents futibatinib and binimetinib in rat plasma: Insights from preclinical pharmacokinetics},
  journal = {Biomedical Chromatography},
  year = {2024},
  volume = {38},
  number = {11},
  doi = {10.1002/bmc.6005}
}
Kostenlos starten →